Tandem Diabetes Care ( TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the ...

Tandem Diabetes Care, Inc.’s TNDM growth is backed by its impressive range of new products. The flourishing diabetes market ...

Capital World Investors (Trades, Portfolio) executed a significant transaction by reducing their holdings in Tandem Diabetes ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Tandem ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following ...

Investing.com - Tandem Diabetes Care (NASDAQ: TNDM) reported third quarter EPS of $-0.51, $0.03 worse than the analyst estimate of $-0.48. Revenue for the quarter came in at... Tandem Diabetes ...

A recent study from Western Sydney University has shown that a simple change in how healthcare providers manage type 2 ...

ScienceDaily: Some Diabetes Drugs Tied To Lower Risk Of Dementia, Parkinson's Disease A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...